Scientists Reverse 60 Years of Cellular Aging, Launch First Human Clinical Trial
Current overview (not historical)
German researchers reprogrammed blood cells from an 80-year-old donor to reverse 60 years of epigenetic aging, converting them into neural stem cells. Subsequently, U.S. regulators approved Life Biosciences to launch the first human clinical trial of ER-100, a therapy targeting aging eye cells. Three glaucoma patients tolerated a 56-day treatment, and two experienced improved vision.
Written with AI from the reporting · updated 10/26/2026
Expand the detailed fact route and sources
Story route
A station-by-station route from the first public evidence onward; every station carries its own evidence and uncertainty.
- 1Unclassified fact stationOct 26, 10:05single sourcereport-time only
科学家逆转60年细胞衰老
Read original source ↗ BeInCryptoReplay this moment in the explorerEvidence & revisions · 1 source records
- Subject：
- University of Bonn
- Action：
- 研究人员将80岁血细胞转化为神经干细胞并逆转其分子年龄
- Object：
- 血细胞
- Occurred (fact side)：
- not recorded
- Published (valid side)：
- Oct 26, 09:56
- First seen (known side)：
- Oct 26, 10:05
Fact stationSingle source · one-sided claimReport-time onlyCopy may have been revised later; time replay is bounded. Layer labels group reading only, not causation between layers.
Uncertainty marks flag where to check the sources; they are not proven causation.
Report timeline
Explore every side through dated source reports.
- BeInCryptoSelectedRelated fact: single sourceFact occurrence time unverifiedScientists reverse 60 years of cellular aging in lab, track rejuvenation for over 100 days
Report first recorded Oct 26, 10:05
Researchers at the University of Bonn converted blood cells from an 80-year-old donor directly into neural stem cells, observing a remarkable reversal of more than 60 years of molecular aging. Using epigenetic clocks, the team tracked the gradual rejuvenation process for over 100 days, distinguishing their method from earlier techniques that reset age rapidly through an intermediate stem-cell stage. The approach offers a new way to study the biological mechanisms of aging and related diseases such as Alzheimer's. In parallel, US regulators cleared Life Biosciences to test ER-100 in human patients, with three glaucoma patients tolerating treatment for 56 days and two showing preliminary vision improvements.
Read original source ↗
Event discussion
Reader opinions are hosted on GitHub Discussions; posting requires a GitHub account. Comments are not verified facts.